Cardiome to Hold Conference Call

Cardiome to Hold Conference Call

VANCOUVER, British Columbia, Sept. 26, 2012 (GLOBE NEWSWIRE) -- Cardiome
Pharma Corp. (Nasdaq:CRME) (TSX:COM) today announced that a teleconference
call and webcast will be held on Wednesday, September 26, 2012 at 9:00 am
Eastern (6:00am Pacific) to discuss Merck's return of the global marketing and
development rights for vernakalant to Cardiome.

To access the conference call, please dial 877-670-9780 and reference
conference 35490705. There will be a separate dial-in line for analysts on
which we will respond to questions at the end of the call. The webcast can be
accessed through Cardiome's website at www.cardiome.com.

Webcast and telephone replays of the conference call will be available
approximately two hours after the completion of the call through October 26,
2012. Please dial 855-859-2056 or 404-537-3406 and enter code 35490705 to
access the replay.

About Cardiome Pharma Corp.

Cardiome Pharma Corp. is a biopharmaceutical company dedicated to the
discovery, development and commercialization of new therapies that will
improve the health of patients around the world. Cardiome has one marketed
product, Brinavess^TM (vernakalant IV), approved in Europe and other
territories for the rapid conversion of recent onset atrial fibrillation to
sinus rhythm in adults.

Cardiome is traded on the NASDAQ Global Market (CRME) and the Toronto Stock
Exchange (COM). For more information, please visit our web site at
www.cardiome.com.

Forward-Looking Statement Disclaimer

Certain statements in this press release contain forward-looking statements
within the meaning of the Private Securities Litigation Reform Act of 1995 or
forward-looking information under applicable Canadian securities legislation
that may not be based on historical fact, including without limitation
statements containing the words "believe", "may", "plan", "will", "estimate",
"continue", "anticipate", "intend", "expect" and similar expressions. Such
forward-looking statements or information involve known and unknown risks,
uncertainties and other factors that may cause our actual results, events or
developments, or industry results, to be materially different from any future
results, events or developments expressed or implied by such forward-looking
statements or information. Risks, uncertainties and factors that could cause
such actual events or results expressed or implied by such forward-looking
statements and information to differ materially from any future events or
results expressed or implied by such statements and information include, but
are not limited to, the risks, uncertainties and factors related to the fact
that: we, together with our collaborative partners, may not be able to
successfully develop all or any of our current or future products and may not
be able to obtain regulatory approval in targeted indications for our current
or future products in all markets; we may not achieve or maintain
profitability; our future operating results are uncertain and likely to
fluctuate; we may not be able to raise additional capital as and when
required; we depend on our collaborative partners to perform their obligations
under licensing or other collaborative agreements; we may not be successful in
establishing additional corporate collaborations or licensing arrangements; we
may not be able to establish marketing and sales capabilities and the costs of
launching our products may be greater than anticipated; any of our products
that obtain regulatory approval will be subject to extensive post-market
regulation that may affect sales, marketing and profitability; any of our
products that are successfully developed may not achieve market acceptance; we
rely on third parties for the continued supply and manufacture of our products
and have no experience in commercial manufacturing; we may face unknown risks
related to intellectual property matters, including with respect to our
ability to protect our intellectual property; we face increased competition
from pharmaceutical and biotechnology companies; and other factors as
described in detail in our filings with the Securities and Exchange Commission
available at www.sec.gov and the Canadian securities regulatory authorities at
www.sedar.com.Given these risks, uncertainties and factors, you are cautioned
not to place undue reliance on such forward-looking statements and
information, which are qualified in their entirety by this cautionary
statement. All forward-looking statements and information made herein are
based on our current expectations and we undertake no obligation to revise or
update such forward-looking statements and information to reflect subsequent
events or circumstances, except as required by law.

CONTACT: For Further Information:
         Cardiome Investor Relations
         (604) 676-6993 or Toll Free: 1-800-330-9928
         Email: ir@cardiome.com
 
Press spacebar to pause and continue. Press esc to stop.